08.05.09
Charles River Laboratories
2Q Revenues: $308.2 million (-13%)
2Q Earnings: $34.2 million (-30%)
FY Revenues: $609.7 million (-12%)
FY Earnings: $59.6 million (-36%)
Comments: Sales declined in both the Research Models and Services (RMS) and Preclinical Services (PCS) segments, reflecting the negative impact of foreign exchange, as well as softer market demand. RMS sales were $165.7 million in the quarter (-4%) and PCS segment sales were $142.5 million (-21%).
Sign up today for Contracting & Outsourcing 2009!
2Q Revenues: $308.2 million (-13%)
2Q Earnings: $34.2 million (-30%)
FY Revenues: $609.7 million (-12%)
FY Earnings: $59.6 million (-36%)
Comments: Sales declined in both the Research Models and Services (RMS) and Preclinical Services (PCS) segments, reflecting the negative impact of foreign exchange, as well as softer market demand. RMS sales were $165.7 million in the quarter (-4%) and PCS segment sales were $142.5 million (-21%).
Sign up today for Contracting & Outsourcing 2009!